Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
PLoS One. 2013 Aug 21;8(8):e72583. doi: 10.1371/journal.pone.0072583. eCollection 2013.
Myeloperoxidase (MPO) is a metabolic/oxidative lysosomal enzyme secreted by reactive neutrophils at the sites of inflamed organs and tissues during phagocytosis. MPO has been either directly or indirectly linked to neoplasia, which is a well-established risk factor for many types of cancer. A large number of studies have reported the role of MPO G-463A polymorphism regarding breast-cancer risk. However, the published findings are inconsistent. Therefore, we conducted a meta-analysis to determine more precise estimations for the relationship. Eligible studies were identified by searching several electronic databases for relevant reports published before June 2012. According to the inclusion criteria and exclusion criteria, a total of five eligible studies were included in the pooled analyses. When the five eligible studies concerning MPO G-463A polymorphism were pooled into this meta-analysis, there was no evidence found for a significant association between MPO G-463A polymorphism and breast-cancer risk in any genetic model. We also categorized by ethnicity (Caucasian or Asian) for subgroup analysis; according to this subgroup analysis, we found no significant association between MPO G-463A polymorphism and breast-cancer risk in any genetic model. However, in the stratified analysis for the premenopausal group, women carrying the AA genotype were found to have a significantly reduced risk (OR = 0.56, 95% CI 0.34-0.94, p = 0.027). Under the recessive model, there was a significant association between MPO G-463A polymorphism and breast-cancer risk (OR = 0.57, 95% CI 0.34-0.93, p = 0.025). We conclude that MPO-G463A polymorphism might not be a good predictor of breast-cancer risk, though menopausal status modified women's risk of developing breast cancer.
髓过氧化物酶 (MPO) 是一种代谢/氧化溶酶体酶，在吞噬过程中由反应性中性粒细胞分泌到发炎的器官和组织部位。MPO 已被直接或间接地与肿瘤发生联系起来，这是许多类型癌症的一个公认的危险因素。大量研究报告了 MPO G-463A 多态性与乳腺癌风险的关系。然而，已发表的研究结果并不一致。因此，我们进行了荟萃分析以确定更准确的估计值。通过搜索几个电子数据库，我们确定了截至 2012 年 6 月之前发表的相关报告，从而确定了符合条件的研究。根据纳入和排除标准，共有五项符合条件的研究纳入了汇总分析。当将五项有关 MPO G-463A 多态性的符合条件的研究纳入荟萃分析时，在任何遗传模型中都没有发现 MPO G-463A 多态性与乳腺癌风险之间存在显著关联的证据。我们还按种族（白种人或亚洲人）进行亚组分析；根据亚组分析，我们没有发现 MPO G-463A 多态性与乳腺癌风险之间存在任何遗传模型的关联。但是，在绝经前组的分层分析中，发现携带 AA 基因型的女性发生乳腺癌的风险显著降低（OR = 0.56，95%CI 0.34-0.94，p = 0.027）。在隐性模型中，MPO G-463A 多态性与乳腺癌风险之间存在显著关联（OR = 0.57，95%CI 0.34-0.93，p = 0.025）。我们的结论是，MPO-G463A 多态性可能不是乳腺癌风险的良好预测指标，尽管绝经状态改变了女性发生乳腺癌的风险。
